Widespread Reimbursement Advancements Recognize the Clinical Value of Plaque Analysis for Physicians and Patients BOSTON–(BUSINESS WIRE)–#CoronaryArteryDisease—Widespread Reimbursement Advancements Recognize the Clinical Value of Plaque Analysis for Physicians and Patients BOSTON–(BUSINESS WIRE)–#CoronaryArteryDisease—

Elucid Announces Broad Reimbursement for Quantitative Coronary Plaque Analysis

2026/01/09 20:16
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Widespread Reimbursement Advancements Recognize the Clinical Value of Plaque Analysis for Physicians and Patients

BOSTON–(BUSINESS WIRE)–#CoronaryArteryDisease—Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.

Quantitative coronary plaque analysis, such as Elucid’s Plaque-IQ™, is now reportable under Category I CPT code 75577, with a national average payment amount of $1,012 for use in imaging centers and physician offices. For hospital outpatient settings, the 2026 Outpatient Prospective Payment System (OPPS) rate has been set at $951. The establishment of CPT code 75577 by the American Medical Association (AMA) provides a standardized code descriptor for quantitative assessment of coronary atherosclerotic plaque using coronary computed tomography angiography (CCTA).

This news is complemented by a coverage decision this week from Aetna, which will begin covering plaque analysis immediately. Aetna’s decision follows similar coverage decisions by Humana, Cigna, and UnitedHealthcare, all aligned with guidelines issued in July 2025 by radiology benefit manager Evicore. Collectively, more than 70 percent of covered Americans now have coverage policies in place for coronary plaque analysis.

“Plaque analysis is quickly becoming an essential tool in my overall patient diagnosis and management, and its adoption will only accelerate as coverage continues to expand,” said Victor Marinescu, MD, a cardiologist at Midwest Cardiovascular Institute in Naperville, Illinois. “I’m particularly intrigued by Elucid‘s histology-based technology and Plaque-IQ’s ability to identify lipid rich necrotic core (LRNC). This additional insight is influencing my diagnostic decisions and shaping how I manage patient care.”

While other plaque analysis technologies are validated against a human eye, Elucid’s Plaque-IQ is the only plaque analysis technology validated in objective ground truth histology, the gold standard for plaque characterization. Powered by CT-Virtual Histology™ (CT-VH™), Plaque-IQ noninvasively quantifies and classifies coronary plaque and its components – including LRNC – providing insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies.1,2

This approach is designed to help physicians prioritize and personalize treatment based on actual coronary artery disease rather than population-based risk estimates.

“Elucid has long been committed to advancing clinically meaningful imaging analytics that support physician decision-making,” said Elucid CEO Kelly Huang, PhD. “The scope, scale and speed of these reimbursement changes are unprecedented, and highlight the clinical value that CT-derived coronary plaque analysis brings to physicians and their patients. These advances reinforce our belief that Plaque-IQ helps physicians make patient-specific decisions around medical management and intervention.”

About Elucid

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary and carotid plaque buildup), the root cause of cardiovascular disease. The company’s Plaque-IQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid’s FFRCT product, which is currently under development, is derived from Elucid’s plaque algorithm, resulting in concordance between plaque and FFRCT. FFRCT helps physicians identify coronary blockages and the extent of a patient’s ischemia non-invasively. For more information, visit elucid.com.

References:

1 https://www.ahajournals.org/doi/10.1161/01.ATV.20.5.1262
2 https://pubmed.ncbi.nlm.nih.gov/39600843/

Contacts

Media Contact:
Sam Choinski

Pazanga Health Communications

(860) 301-5058

schoinski@pazangahealth.com

Market Opportunity
IQ Logo
IQ Price(IQ)
$0.001027
$0.001027$0.001027
-0.29%
USD
IQ (IQ) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

A heated contest for control over a new dollar-pegged token has set the stage for what analysts say could define the next phase of the stablecoin industry. According to Bloomberg, a bidding war unfolded on Hyperliquid, one of crypto’s fastest-growing trading platforms, with the prize being the right to issue USDH, its native stablecoin. The competition drew some of the sector’s most prominent names, including Paxos, Sky, and Ethena, who later withdrew their bid, alongside the lesser-known Native Markets, a startup backed by Stripe stablecoin subsidiary Bridge. Hyperliquid Stablecoin Race Shows Branding and Partnerships Matter as Much as Tech Over the weekend, Hyperliquid’s validators, the contributors who secure the network and vote on key decisions, awarded the USDH contract to Native Markets over the weekend. Despite its relatively new status, the firm’s connection with Stripe helped it outpace more established rivals. Stablecoins underpin decentralized finance by providing a dollar-backed medium for collateral, settlement, and payments across applications. What began as a grassroots, community-led sector has evolved into a battleground for institutions and payment companies seeking revenue from interest on reserves. Circle, for example, shares proceeds from its USDC with Coinbase under a partnership designed to stabilize earnings during market swings. The Hyperliquid contest offered a rare glimpse into just how intense competition has become. Paxos pledged to take no revenue until USDH surpassed $1 billion in circulation. Agora offered to share 100% of net revenue with Hyperliquid, while Ethena put forward 95%. All were outbid by Native Markets, whose ties to Stripe’s $1.1 billion acquisition of Bridge and subsequent rollout of the Tempo blockchain positioned it as a strong contender. “Every stablecoin issuer is extremely desperate for supply,” said Zaheer Ebtikar, co-founder of Split Capital. “They are willing to publicly announce how much they are willing to offer. It just shows it’s a very tough business for stablecoin issuers.” While USDC remains dominant on Hyperliquid with more than $5.6 billion in deposits, the arrival of USDH could shift flows and revenue dynamics. Paxos co-founder Bhau Kotecha said the firm sees the exchange’s growth as an important opportunity, while Agora’s co-founder Nick van Eck warned that awarding the contract to a vertically integrated issuer risked undermining decentralization. Regulatory positioning also factored into the debate. Paxos operates under a New York trust charter and is seeking a federal license, while Bridge holds money transmitter approvals in 30 states. Native Markets, in a blog post, cited regulatory flexibility and deployment speed as reasons for its selection. Hyperliquid said the strong engagement from its community validated the process. Circle CEO Jeremy Allaire dismissed concerns over USDC’s status, noting on X that competition benefits the ecosystem. Analysts suggested that fears of centralization may be exaggerated, noting that Hyperliquid is likely to remain neutral and support multiple stablecoins. Still, the contest over USDH highlighted a new reality for stablecoins: branding, partnerships, and business strategy are becoming as decisive as technology. Native Markets Secures USDH Stablecoin Mandate on Hyperliquid Hyperliquid has concluded its governance vote for the USDH stablecoin, awarding the mandate to Native Markets after a closely watched process that drew weeks of community debate and rival proposals. USDH, described by Hyperliquid as a “Hyperliquid-first, compliant, and natively minted” dollar-backed token, is intended to reduce the platform’s dependence on USDC and strengthen its spot markets. Validators on the decentralized exchange voted in favor of Native Markets, a relatively new player backed by Stripe’s Bridge subsidiary, over established contenders including Paxos and Ethena. The outcome followed a string of proposals offering aggressive revenue-sharing terms to win validator support, underscoring the scale of incentives attached to controlling USDH. Hyperliquid’s exchange has become a critical hub for stablecoin liquidity, with $5.7 billion in USDC, around 8% of its total supply, currently held on the network. At prevailing treasury yields, that translates to an estimated $200 million to $220 million in annual revenue for Circle, underlining why a native alternative could be transformative. Hyperliquid’s validators, who secure the network and vote on key decisions, selected Native Markets following an on-chain governance process that concluded September 15. Native Markets has laid out a phased rollout for USDH, beginning with capped minting and redemption trials before expanding into spot markets. Its reserves will be managed in cash and treasuries by BlackRock, with on-chain tokenization through Superstate and Bridge. Yield from those reserves will be split between Hyperliquid’s Assistance Fund and ecosystem development. The launch of USDH comes as Hyperliquid records record profits from perpetual futures trading, with $106 million in revenue in August alone, and prepares to slash spot trading fees by 80% to bolster liquidity. Analysts say the move positions Hyperliquid to capture more of the stablecoin economics internally, marking a significant step in its bid to rival the largest players in decentralized finance
Share
CryptoNews2025/09/18 00:48
Bitcoin Market Faces Renewed Pressure: What Lies Ahead?

Bitcoin Market Faces Renewed Pressure: What Lies Ahead?

The post Bitcoin Market Faces Renewed Pressure: What Lies Ahead? appeared on BitcoinEthereumNews.com. Recent data reveals heightened instability in the cryptocurrency
Share
BitcoinEthereumNews2026/03/31 01:21
BTC fell below $67,000, down 0.94% on the day.

BTC fell below $67,000, down 0.94% on the day.

PANews reported on March 31 that, according to OKX market data, BTC has just fallen below $67,000 and is currently trading at $66,989.20 per coin, down 0.94% on
Share
PANews2026/03/31 01:22